Marble D A, Bosso J A
Drug Intell Clin Pharm. 1986 Apr;20(4):261-6. doi: 10.1177/106002808602000402.
Norfloxacin is a quinoline (quinolinecarboxylic acid) that should prove successful in treating infections that currently require hospitalization and intravenous antibiotics. Although a nalidixic acid derivative, it possesses greater antibacterial activity against gram-positive and gram-negative bacteria. Compared with other antimicrobial agents, norfloxacin is more potent than the aminoglycosides, first-, second-, and third-generation cephalosporins, tetracycline, trimethoprim-sulfamethoxazole, carbenicillin, piperacillin, nalidixic acid, oxolinic acid, cinoxacin, and enoxacin. In the clinical studies to date, the side effects of norfloxacin have been minimal, but include nausea, vomiting, anorexia, dizziness, headache, drowsiness, depression, and a bitter taste in the mouth. In studies with more than 4000 patients, the incidence of side effects ranged from 3.9 to 4.7 percent, with most appearing by the second day of therapy.
诺氟沙星是一种喹啉(喹啉羧酸),对于治疗目前需要住院并使用静脉抗生素的感染应该会取得成功。尽管它是萘啶酸的衍生物,但对革兰氏阳性菌和革兰氏阴性菌具有更强的抗菌活性。与其他抗菌药物相比,诺氟沙星比氨基糖苷类、第一代、第二代和第三代头孢菌素、四环素、甲氧苄啶 - 磺胺甲恶唑、羧苄青霉素、哌拉西林、萘啶酸、恶喹酸、西诺沙星和依诺沙星更有效。在迄今为止的临床研究中,诺氟沙星的副作用极小,但包括恶心、呕吐、厌食、头晕、头痛、嗜睡、抑郁和口苦。在超过4000名患者的研究中,副作用发生率在3.9%至4.7%之间,大多数在治疗第二天出现。